Gilead Sciences, Inc. $GILD Stock: MH & Associates Securities Management Corp ADV Decreases Stake

MH & Associates Securities Management Corp ADV lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.5% in the third quarter, Holdings Channel.com reports. The fund owned 17,668 shares of the biopharmaceutical company’s stock after selling 8,493 shares during the period. Gilead Sciences comprises approximately 2.3% of MH & Associates Securities Management Corp ADV’s portfolio, making the stock its 22nd largest holding. MH & Associates Securities Management Corp ADV’s holdings in Gilead Sciences were worth $2,633,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. BlackRock Inc. purchased a new position in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. State Street Corp lifted its position in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Amundi lifted its position in shares of Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Legal & General Group Plc bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $1,316,606,000. Finally, Deutsche Bank AG bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $918,387,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the insider directly owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the sale, the chief financial officer directly owned 161,096 shares in the company, valued at $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 126,881 shares of company stock worth $19,252,455. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $174.48 on Thursday. The company has a market capitalization of $216.41 billion, a price-to-earnings ratio of -55.22 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $175.65. The company’s 50-day moving average is $152.29 and its 200 day moving average is $140.52.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the prior year, the firm posted $2.47 earnings per share. The business’s revenue was up 6.8% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post -1.07 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 1.9%. Gilead Sciences’s dividend payout ratio is -103.80%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: DZ Bank raised its price target on Gilead to $191 from $167, signaling increased confidence in the stock’s prospects. DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
• Positive Sentiment: Gilead and its Kite subsidiary plan 23 presentations, including seven oral presentations, at the December ASH meeting. The breadth of planned data across the pipeline and portfolio may draw investor attention to potential growth drivers. Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
• Positive Sentiment: BioNTech and Gilead are advancing a global Phase 3 trial combining BioNTech’s pumitamig with Gilead’s cancer drug Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. The collaboration expands the potential reach of Gilead’s oncology portfolio, though trial results remain to come. BioNTech Enters First Global Phase 3 Trial for New Breast Cancer Combo
• Neutral Sentiment: Gilead’s GS-1206 cancer study continues to advance, but investors are still waiting for early efficacy signals; the update did not provide results that establish the drug’s potential. Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals
• Negative Sentiment: Put-option purchases were unusually elevated, which may reflect increased hedging or bearish positioning, though options activity alone does not confirm a negative outlook.
• Negative Sentiment: CEO Daniel O’Day disclosed recent stock sales under a pre-arranged Rule 10b5-1 plan. The planned nature of the sales may limit their significance, but insider selling can still weigh on sentiment.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on GILD. Bank of America increased their price target on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research note on Tuesday, October 20th. BMO Capital Markets reiterated an “outperform” rating and set a $184.00 target price on shares of Gilead Sciences in a report on Friday, October 30th. TD Cowen increased their target price on Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. UBS Group raised their target price on Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Finally, Morgan Stanley lifted their price target on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $170.15.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.